322 related articles for article (PubMed ID: 28284752)
21. Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice.
Burgaz S; García C; Gómez-Cañas M; Navarrete C; García-Martín A; Rolland A; Del Río C; Casarejos MJ; Muñoz E; Gonzalo-Consuegra C; Muñoz E; Fernández-Ruiz J
Mol Cell Neurosci; 2021 Jan; 110():103583. PubMed ID: 33338634
[TBL] [Abstract][Full Text] [Related]
22. Neuroprotective Effects of Tanshinone I Against 6-OHDA-Induced Oxidative Stress in Cellular and Mouse Model of Parkinson's Disease Through Upregulating Nrf2.
Jing X; Wei X; Ren M; Wang L; Zhang X; Lou H
Neurochem Res; 2016 Apr; 41(4):779-86. PubMed ID: 26537816
[TBL] [Abstract][Full Text] [Related]
23. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.
Migliore MM; Ortiz R; Dye S; Campbell RB; Amiji MM; Waszczak BL
Neuroscience; 2014 Aug; 274():11-23. PubMed ID: 24845869
[TBL] [Abstract][Full Text] [Related]
24. Involvement of BDNF/TrkB signaling in the effect of diphenyl diselenide on motor function in a Parkinson's disease rat model.
Sampaio TB; Pinton S; da Rocha JT; Gai BM; Nogueira CW
Eur J Pharmacol; 2017 Jan; 795():28-35. PubMed ID: 27915043
[TBL] [Abstract][Full Text] [Related]
25. Puerarin protects dopaminergic neurons against 6-hydroxydopamine neurotoxicity via inhibiting apoptosis and upregulating glial cell line-derived neurotrophic factor in a rat model of Parkinson's disease.
Zhu G; Wang X; Chen Y; Yang S; Cheng H; Wang N; Li Q
Planta Med; 2010 Nov; 76(16):1820-6. PubMed ID: 20509103
[TBL] [Abstract][Full Text] [Related]
26. Squamosamide derivative FLZ protected dopaminergic neuron by activating Akt signaling pathway in 6-OHDA-induced in vivo and in vitro Parkinson's disease models.
Bao XQ; Kong XC; Kong LB; Wu LY; Sun H; Zhang D
Brain Res; 2014 Feb; 1547():49-57. PubMed ID: 24384139
[TBL] [Abstract][Full Text] [Related]
27. Troxerutin exerts neuroprotection against lipopolysaccharide (LPS) induced oxidative stress and neuroinflammation through targeting SIRT1/SIRT3 signaling pathway.
Jamali-Raeufy N; Kardgar S; Baluchnejadmojarad T; Roghani M; Goudarzi M
Metab Brain Dis; 2019 Oct; 34(5):1505-1513. PubMed ID: 31313124
[TBL] [Abstract][Full Text] [Related]
28. EPO-dependent activation of PI3K/Akt/FoxO3a signalling mediates neuroprotection in in vitro and in vivo models of Parkinson's disease.
Jia Y; Mo SJ; Feng QQ; Zhan ML; OuYang LS; Chen JC; Ma YX; Wu JJ; Lei WL
J Mol Neurosci; 2014 May; 53(1):117-24. PubMed ID: 24390959
[TBL] [Abstract][Full Text] [Related]
29. The ameliorative effect of Monascus purpureus NTU 568-fermented rice extracts on 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells and the rat model of Parkinson's disease.
Tseng WT; Hsu YW; Pan TM
Food Funct; 2016 Feb; 7(2):752-62. PubMed ID: 26809317
[TBL] [Abstract][Full Text] [Related]
30. Edaravone protects neurons in the rat substantia nigra against 6-hydroxydopamine-induced oxidative stress damage.
Liu X; Shao R; Li M; Yang G
Cell Biochem Biophys; 2014 Nov; 70(2):1247-54. PubMed ID: 24948472
[TBL] [Abstract][Full Text] [Related]
31. Post-lesion administration of 7-NI attenuated motor and non-motor deficits in 6-OHDA induced bilaterally lesioned female rat model of Parkinson's disease.
Kumari R; Kumar JB; Luthra PM
Neurosci Lett; 2015 Mar; 589():191-5. PubMed ID: 25528406
[TBL] [Abstract][Full Text] [Related]
32. Resveratrol delays 6-hydroxydopamine-induced apoptosis by activating the PI3K/Akt signaling pathway.
Huang N; Zhang Y; Chen M; Jin H; Nie J; Luo Y; Zhou S; Shi J; Jin F
Exp Gerontol; 2019 Sep; 124():110653. PubMed ID: 31295526
[TBL] [Abstract][Full Text] [Related]
33. Neuroprotective effect of bioflavonoid quercetin in 6-hydroxydopamine-induced oxidative stress biomarkers in the rat striatum.
Haleagrahara N; Siew CJ; Mitra NK; Kumari M
Neurosci Lett; 2011 Aug; 500(2):139-43. PubMed ID: 21704673
[TBL] [Abstract][Full Text] [Related]
34. Alpha-lipoic acid protects against 6-hydroxydopamine-induced neurotoxicity in a rat model of hemi-parkinsonism.
Jalali-Nadoushan M; Roghani M
Brain Res; 2013 Apr; 1505():68-74. PubMed ID: 23415934
[TBL] [Abstract][Full Text] [Related]
35. Neuroprotection by 6-(methylsulfinyl)hexyl isothiocyanate in a 6-hydroxydopamine mouse model of Parkinson׳s disease.
Morroni F; Sita G; Tarozzi A; Cantelli-Forti G; Hrelia P
Brain Res; 2014 Nov; 1589():93-104. PubMed ID: 25257035
[TBL] [Abstract][Full Text] [Related]
36. Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons.
Yuan WJ; Yasuhara T; Shingo T; Muraoka K; Agari T; Kameda M; Uozumi T; Tajiri N; Morimoto T; Jing M; Baba T; Wang F; Leung H; Matsui T; Miyoshi Y; Date I
BMC Neurosci; 2008 Aug; 9():75. PubMed ID: 18671880
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the neuroprotective potential of caffeic acid phenethyl ester in a cellular model of Parkinson's disease.
Turan D; Abdik H; Sahin F; Avşar Abdik E
Eur J Pharmacol; 2020 Sep; 883():173342. PubMed ID: 32634439
[TBL] [Abstract][Full Text] [Related]
38. Potential neuroprotective effect of androst-5-ene-3β, 17β-diol (ADIOL) on the striatum, and substantia nigra in Parkinson's disease rat model.
Salama RM; Tadros MG; Schaalan MF; Bahaa N; Abdel-Tawab AM; Khalifa AE
J Cell Physiol; 2018 Aug; 233(8):5981-6000. PubMed ID: 29266208
[TBL] [Abstract][Full Text] [Related]
39. Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease.
Zbarsky V; Datla KP; Parkar S; Rai DK; Aruoma OI; Dexter DT
Free Radic Res; 2005 Oct; 39(10):1119-25. PubMed ID: 16298737
[TBL] [Abstract][Full Text] [Related]
40. Oral pelargonidin exerts dose-dependent neuroprotection in 6-hydroxydopamine rat model of hemi-parkinsonism.
Roghani M; Niknam A; Jalali-Nadoushan MR; Kiasalari Z; Khalili M; Baluchnejadmojarad T
Brain Res Bull; 2010 Jul; 82(5-6):279-83. PubMed ID: 20558255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
